Literature DB >> 21412567

Impact of HAART on growth and hospitalization rates among HIV-infected children.

Lilian Martins Oliveira Diniz1, Marcelle Marie Martins Maia, Letícia Silveira Camargos, Leandro Custódio Amaral, Eugênio Marcos Andrade Goulart, Jorge Andrade Pinto.   

Abstract

OBJECTIVE: To evaluate HAART-associated changes in growth and hospitalization rates over time in a cohort of HIV-infected children.
METHODS: Children starting HAART were assessed during the first 3 years of therapy. Clinical response was assessed every 24 weeks by z scores of weight-for-age and height-for-age. Linear regression models were used to detect predictors of clinical response. Pertinent information on hospitalizations was obtained retrospectively through review of medical records.
RESULTS: A total of 196 children were assessed. Mean weight z score increased from -1.62 (±1.32) at baseline to -1.14 (±1.12) by week 24. Mean height z score increased from -1.88 (±1.45) at baseline to -1.66 (±1.18). Better z scores at baseline were associated with greater increases in weight z scores over time. Lower viral load and higher height z scores at baseline were also associated with improved height catch-up. Eighty-five children (43.3%) were hospitalized. Most hospitalizations were prompted by infectious disease, with only two due to opportunistic infections.
CONCLUSION: HAART was associated with significant increases in weight and height z scores. Younger age, the use of protease inhibitors and advanced clinical disease were associated with better outcomes. The present study demonstrated the effectiveness of HAART in significantly reducing hospitalization, death, and incidence of opportunistic infections among HIV-infected children.

Entities:  

Mesh:

Year:  2011        PMID: 21412567     DOI: 10.2223/JPED.2064

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  7 in total

1.  Growth among HIV-infected children receiving antiretroviral therapy in Dar es Salaam, Tanzania.

Authors:  Ramadhani S Mwiru; Donna Spiegelman; Christopher Duggan; George R Seage; Helen Semu; Guerino Chalamilla; Rodrick Kisenge; Wafaie W Fawzi
Journal:  J Trop Pediatr       Date:  2014-01-06       Impact factor: 1.165

Review 2.  Growth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis.

Authors:  Christine J McGrath; Lara Diener; Barbra A Richardson; Elizabeth Peacock-Chambers; Grace C John-Stewart
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

3.  Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa.

Authors:  Brian C Zanoni; Thuli Phungula; Holly M Zanoni; Holly France; E Francis Cook; Margaret E Feeney
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

4.  Morbidity and Mortality of a Cohort of Peruvian HIV-infected Children 2003-2012.

Authors:  Amira N Baker; Angela M Bayer; Rolando M Viani; Lenka Kolevic; Myung-Shin Sim; Jaime G Deville
Journal:  Pediatr Infect Dis J       Date:  2018-06       Impact factor: 3.806

5.  Poor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagement.

Authors:  Sten H Vermund; Meridith Blevins; Troy D Moon; Eurico José; Linda Moiane; José A Tique; Mohsin Sidat; Philip J Ciampa; Bryan E Shepherd; Lara M E Vaz
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

6.  Predictors of Hospitalization among Children on ART in Ethiopia: a Cohort study.

Authors:  Abraham Haileamlak; Tesfalem Hagos; Workeabeba Abebe; Loko Abraham; Henok Asefa; Alula M Teklu
Journal:  Ethiop J Health Sci       Date:  2017-02

7.  Impact of antiretroviral treatment on height evolution of HIV infected children.

Authors:  Patrinee Traisathit; Saïk Urien; Sophie Le Coeur; Sakulrat Srirojana; Noppadon Akarathum; Suparat Kanjanavanit; Chaiwat Ngampiyaskul; Sawitree Krikajornkitti; Nicole Ngo-Giang-Huong; Marc Lallemant; Gonzague Jourdain
Journal:  BMC Pediatr       Date:  2019-08-17       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.